We all exhibit behaviours that are, at times, irrational, and this presents a major challenge for pharmaceutical companies that are developing patient support programmes.
Brexit, and the political fallout from approving any deal, will continue to dominate British politics in 2019. It will shape some of the biggest decisions the UK has made since 1945.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
